Plasma protein metabolism disease
MONDO:0002273An inherited metabolic disorder that involves plasma protein metabolism malfunction.
67 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Experimental KRRO-110 trial for rare lung condition halted early
Disease control TerminatedThis study tested an experimental drug called KRRO-110 in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can cause lung and liver damage. The goal was to check safety and how the drug moves through the body. However, the trial w…
Phase: PHASE1, PHASE2 • Sponsor: Korro Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Promising liver drug trial halted early: what it means for patients
Disease control TerminatedThis study tested a new drug called belcesiran in people with a genetic condition called alpha-1 antitrypsin deficiency that causes liver damage. The goal was to see if the drug is safe and can lower harmful protein levels in the liver. The trial was stopped early, so results are…
Phase: PHASE2 • Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental drug for rare lung disease shows early promise but trial halted
Disease control TerminatedThis early-phase study tested a drug called ARC-AAT in healthy volunteers and people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can lead to lung and liver damage. The main goal was to check safety and how the drug affects levels of a key protein in the b…
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental pill for rare lung and liver disease hits snag: trial stopped early
Disease control TerminatedThis study tested an experimental drug called VX-864 in 14 people with a severe form of alpha-1 antitrypsin deficiency (PiZZ genotype). The goal was to see if the pill could raise protective protein levels in the blood and reduce harmful buildup in the liver. The trial was termin…
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC